Lexicon Pharma shares halted pending news

|About: Lexicon Pharmaceutical... (LXRX)|By:, SA News Editor

Nasdaq has suspended trading in Lexicon Pharmaceuticals (LXRX -5.3%) pending the release of news, a near-certainty that it pertains to the expected FDA nod for Sanofi's (SNY -2.6%) oral Zynquista (sotagliflozin) for type 1 diabetes. Today is the agency's action date.

Sanofi in-licensed the dual SGLT-1 & 2 inhibitor from Lexicon in November 2015.

Approval should trigger a milestone payment to LXRX.

Subscribe for full text news in your inbox